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with higher risk of VTE recurrence in female patients (HR 
5.94, 95% CI 1.25–28.13) after adjusting for family history, 
risk of thrombophilia and DVT location. No association 
between TLR9 polymorphism and risk of VTE recurrence 
was found in male patients. Our results suggest that TLR9 
rs5743836 polymorphism is an independent risk factor for 
VTE recurrence in female patients but not in males.
Keywords Recurrent VTE · Multivariate analysis · Toll-
like receptor
Introduction
Venous thromboembolism (VTE) consists of two related 
conditions: deep vein thrombosis (DVT) and pulmonary 
embolism (PE) [1]. Primarily, it was considered to be a 
complication of hospitalization after major surgery. How-
ever, prior epidemiological studies have reported that about 
half of the patients, which had been diagnosed with VTE, 
were those who had never been hospitalized nor had any 
major illness [1, 2]. VTE is a potentially lethal disease 
that occurs with an incidence rate of 1–2 cases per 1000 
person-years [2, 3]. About two-thirds of the patients diag-
nosed with symptomatic VTE had DVT and one-third had 
PE [2]. The mortality rate after 30 days of diagnosis with 
DVT was reported as 4.6%, with PE as 9.7 and 6.4% for 
patients diagnosed with VTE (both DVT and PE) [4]. VTE 
is a chronic disease and patients that have experienced one 
episode of VTE are always at the risk of recurrence and the 
risk is highest during the first 6–12 months [5]. The cumu-
lative rate of VTE recurrence increases with time; 17.5% 
after 2  years, 24.96% after 5  years and rises up to 30.3% 
after 8 years from the first diagnosis with primary VTE [6]. 
Patients with unprovoked VTE (without known acquired 
Abstract Recent gene knockout studies on mice have 
shown the role of toll-like receptor 9 (TLR9) in resolu-
tion of venous thromboembolism (VTE) through sterile 
inflammation. However, the role of a putative functional 
TLR9 polymorphism (rs5743836) in risk assessment of 
VTE recurrence remains unknown. The aim of our study 
was to investigate the TLR9 rs5743836 polymorphism 
in VTE patients and its association with the risk of VTE 
recurrence. We analyzed TLR9 rs5743836 polymorphism 
in Malmö thrombophilia study patients; a prospective fol-
low-up study of 1465 VTE patients by Taqman PCR. From 
a total of 1465 VTE patients, those who had VTE before 
inclusion and those who died or had VTE recurrence dur-
ing anticoagulant treatment were excluded (n = 415). 
Cox regression analyses were performed on the remain-
ing 1050 VTE patients, including 126 (12.5%) patients 
that had recurrent VTE during follow-up period. TLR9 
polymorphism was significantly associated with higher 
risk of VTE recurrence in female patients (HR 3.46, 95% 
CI 1.06–11.33) independent of acquired risk factors for 
VTE, family history, risk of thrombophilia and deep vein 
thrombosis (DVT) location. Similarly, in unprovoked VTE 
patients, TLR9 polymorphism was significantly associated 
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risk factors for VTE, e.g., older age, immobilization, 
trauma, major surgery, female hormone therapy, pregnancy 
etc.) are at higher risk of VTE recurrence as compared to 
provoked VTE (patients with acquired risk factors) [7].
VTE patients are treated with standard treatment pro-
tocol, i.e., anticoagulant therapy for several months which 
protects patients from VTE recurrence, however, at the cost 
of severe bleeding [8, 9]. Regardless of the several identi-
fied risk factors, such as sex, D-dimers level and residual 
thrombosis, it is still difficult to precisely predict the prob-
ability of VTE recurrence after stopping the anticoagula-
tion treatment [8–10]. Moreover, anticoagulants prevent the 
formation of new blood clots but do not remove the exist-
ing thrombi, which undergo a slow process of natural reso-
lution by organization and vein recanalization [11].
Although a number of genes are identified as risk fac-
tors for VTE, the major portion of the heritability remains 
unknown. Twins and familial studies have reported that the 
heritability cause of VTE is up to 60%, and most of these 
genetic factors are still unknown [12, 13]. It is therefore 
clinically relevant to identify new biomarkers that allow 
early prediction of patients at risk of VTE recurrence in 
order to tailor anti-coagulant therapy.
VTE pathophysiology is now better understood follow-
ing several experimental studies. It is believed that inflam-
mation plays a major role in VTE pathophysiology [14]. 
Studies conducted in the 1970s using radiolabel leukocytes 
showed that there is an uptake of white blood cells in the 
venous thrombus [15, 16]. Furthermore, plasma levels of 
C-reactive protein (CRP), a prominent acute-phase reactant 
and inflammatory marker, are known to increase in DVT 
patients [17]. Moreover, clinically it is apparent that VTE 
patients manifest the cardinal signs of inflammation (heat, 
redness, pain and swelling). Thus, inflammation is consid-
ered to have a pivotal role in VTE formation.
Venous thrombus formation, propagation and its disso-
lution is a balance between two mechanisms, i.e. coagula-
tion and innate immune mechanisms [14]. DVT resolution 
is an inflammatory process (known as sterile inflammation) 
which is similar to that of sterile wound healing. It occurs 
naturally through a process of tissue organization includ-
ing neovascularization [14, 18]. Fibrinogen, in venous 
thrombus, along with its degradation products is present 
in abundance and these molecules stimulate the activation 
of the innate immune system to produce cytokines and 
chemokines that are involved in the sterile inflammatory 
process [19].
TLRs are important members of the innate immune sys-
tem. Among the TLR family, TLR9 has been studied for its 
role in VTE resolution. Leukocytes (monocytes, neutro-
phils, lymphocytes and dendritic cells) express TLR9 on 
their membranes [20, 21]. Animal studies show that dele-
tion of the TLR9 gene severely restricts the VTE resolution 
process, which suggests that TLR9 is an important player in 
venous thrombus resolution by modulating sterile inflam-
mation [22, 23]. TLR9 gene has been found to be poly-
morphic in several diseases [24–27]. One of the putative 
functional polymorphism is TLR9 rs5743836 polymor-
phism (−1237T/C polymorphism), which is located within 
the promoter region of TLR9 gene and has been studied 
in several diseases including cardiovascular, cancers and 
autoimmune diseases [27–30]. Since this polymorphism 
(TLR9 rs5743836 polymorphism) is shown to affect the 
transcription of TLR9 gene, and TLR9 gene is involved in 
VTE resolution, it is worthwhile to investigate the role of 
TLR9 rs5743836 polymorphism in recurrent VTE patients 
and its association with the risk of VTE recurrence. To our 
knowledge, this is the first study in which TLR9 rs5743836 
polymorphism has been studied in a well-established VTE 
cohort to investigate its association with the risk of VTE 
recurrence. Novel knowledge will therefore be obtained 




A prospective population-based study of 1465 consecu-
tive unselected VTE patients [Malmö thrombophilia study 
(MATS)] was performed at Skåne University Hospi-
tal. MATS is a well characterized cohort including VTE 
patients that were followed after inclusion (March 1998), 
until VTE recurrence or death of the patient or end of the 
study (December 2008) [31, 32]. For all MATS patients, 
VTE events prior to inclusion, location of DVT, immobi-
lization and cast therapy, hospitalization, surgical inter-
vention, malignancies that were diagnosed previously or 
at diagnosis of VTE, use of contraceptive pills, hormonal 
therapy, pregnancy and postpartum period (first 6  weeks 
after delivery), family history of VTE (history of VTE in 
first-degree relatives), and VTE recurrence during the fol-
low-up period were recorded. All hospital records for VTE 
patients were screened by a research nurse. The rate of con-
sensual participation in this study was 70%. The remaining 
patients (30%) were excluded from the study because they 
refused to participate or did not give consent for the blood 
sampling or could not complete the questionnaire for the 
risk factor analysis due to dementia, language problems or 
presence of other severe diseases.
The inclusion criteria in MATS were: diagnosis of DVT 
and/or PE. VTE diagnosis was objectively confirmed by 
phlebography, computed tomography (CT), duplex ultra-
sonography, lung scintigraphy or magnetic resonance imag-
ing (MRI).
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All MATS patients were treated according to the stand-
ard treatment protocol of Malmö University Hospital, i.e., 
all patients were initially treated with low molecular weight 
heparin or unfractionated heparin and then with warfa-
rin as an oral anticoagulant. The hospital treatment pro-
tocol recommended therapy for 3–6  months for first-time 
VTE, with consideration of extended treatment in case of 
recurrent VTE. A total of 18% of patients were treated for 
>1 year or for life. Thrombophilia was defined as presence 
of the factor V Leiden (FVL) mutation (rs6025) or factor 
II G20210A mutation (rs1799963), or a level below the 
laboratory reference range of protein C [<0.7 kilo inter-
national unit (kIU/L)], free protein S (women < 0.5 kIU/L, 
men < 0.65 kIU/L) or antithrombin (<0.82  kIU/L) in 
patients without warfarin treatment.
Follow-up period (Mean ± SD, 3.9 ± 2.5) was counted 
in years after stopping the anticoagulant treatment until the 
diagnosis of VTE, death of the patient or the end of study 
(December 2008). This study was approved by the ethical 
committee of Lund University. All the participants pro-
vided written permission before their inclusion in the study 
according to the declaration of Helsinki.
Laboratory methods
DNA from the whole blood was extracted by using QiAmp 
96 DNA Blood Kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s instructions. Genotyping of TLR9 
rs5743836 polymorphism was performed by TaqMan® 
SNP Genotyping Assay according to the manufacturer’s 
protocol (Applied Biosystems, Life Technologies Corpo-
ration, Carlsbad, CA, USA). To summarize, a polymerase 
chain reaction (PCR) master mix was prepared as 2.5  µL 
Taqman master mix, 0.25 µL Taqman gene-specific assay 
(VIC and FAM probes for TLR9 rs5743836 polymorphism) 
and 0.25 µL deionized water. Master Mix (3 µL) was added 
to each well in 384 wells PCR plate followed by addition 
of 10  ng DNA. PCR plate was vortexed and centrifuged 
at 1000  rpm (revolutions per minute) for 30  s. BioRad 
CFX384 real-time PCR (1000 Alfred Nobel Drive Hercu-
les, California 94547 USA), according to manufacturer’s 
instructions, was used for polymorphism analysis with the 
following temperature conditions: 95 °C for 10  min fol-
lowed by 40 × (92 °C for 15  s, 60 °C for 1 min). Different 
alleles of TLR9 rs5743836 polymorphism were determined 
by using BioRad CFX manager software.
Analysis of known thrombophilic variants
FVL and factor II G20210A mutations in DNA were ana-
lyzed by TaqMan allele discrimination assays (Applied 
Biosystems) as described previously [33]. Analysis of 
free Protein S was performed by latex immunoassay with 
 Coamatic® Protein S-Free (Chromogenix, Haemochrom 
Diagnostica AB, Gothenburg, Sweden) [34]. Protein C 
levels were analyzed by chromogenic method using the 
 Berichrom® Protein C reagent (Siemens Healthcare Diag-
nostics, Upplands Väsby, Sweden) [35]. For antithrom-
bin analysis, thrombin-based method using Berichrom 
Antithrombin (Siemens Healthcare Diagnostics) was used 
[36]. BCS-XP coagulation analyzer (Siemens Healthcare 
Diagnostics) was used to perform these analyses.
Statistical analysis
Statistical analyses were performed by using SPSS ver-
sion 21 (IBM, Armonk, NY, USA). Dichotomous vari-
ables were compared by Chi square test or Fisher’s exact 
test, where appropriate and continuous variables were 
compared by Mann–Whitney U test. Interaction term 
analysis was performed to test for an interaction between 
TLR9 rs5743836 polymorphism and gender of the patients. 
Kaplan–Meier survival curves for time to recurrent VTE 
by TLR9 rs5743836 polymorphism genotypes were plotted 
and the log-rank test was used to compare recurrence-free 
survival between genotypes. Hardy–Weinberg equilibrium 
analysis was performed to observe the genotypic distribu-
tion. Univariate and multivariate Cox regression analyses 
were performed using Cox proportional hazards models, 
after adjusting for location of DVT, family history of VTE, 
mild and severe thrombophilia and acquired risk factors for 
VTE. For each group of patients, hazard ratios (HRs) with 
95% confidence intervals (CIs) were calculated. Multivari-
ate Cox regression analyses were performed as sensitivity 
analyses by including all VTE patients, with exception for 
those which had thrombotic events before inclusion. The 
follow-up period for sensitivity analyses was calculated 
from the time of inclusion and was adjusted for the dura-
tion of anticoagulation treatment.
Results
Clinical data of the patients
From a total of 1465 patients, those who had thrombotic 
events before inclusion (n = 154) were excluded. For the 
remaining patients (n = 1311), 148 (11.3%) had VTE 
recurrence during the follow-up period. Frequency of 
FVL mutation was higher in patients with recurrent VTE 
(40.8%) as compared to those with non-recurrent VTE 
(28.5%) (P = 0.002). Of the patients with recurrent VTE, 
32.4% had a family history of VTE as compared to 23.5% 
in non-recurrent VTE (P = 0.024). Whereas, no significant 
difference was observed among recurrent and non-recurrent 
VTE patients in age, sex, deep vein thrombosis (DVT), 
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pulmonary embolism (PE), body mass index (BMI), pro-
tein C, protein S and antithrombin deficiency (P > 0.05) 
Table 1.
TLR9 rs5743836 polymorphism has three genotypic 
forms, homozygous wild type (TT), heterozygous (TC) and 
homozygous mutated form (CC). In data analysis, all three 
genotypic forms were analyzed separately as well as by 
combining homozygous wild type and heterozygous form 
(Table 1).
In Hardy–Weinberg equilibrium analyses, genotypic dis-
tributions in TLR9 rs5743836 polymorphism did not devi-
ate significantly (P > 0.05).
TLR9 rs5743836 polymorphism and risk of VTE 
recurrence
For the recurrence analyses of the patients (n = 1311), those 
who had recurrence or died during anticoagulant treatment 
were excluded (n = 261). Analyses were performed on the 
remaining 1050 patients including 126 (12%) recurrent 
VTE patients.
For TLR9 rs5743836 polymorphism, univariate and 
multivariate Cox regression analyses were performed with 
individual genotypes (TT, TC and CC) to investigate their 
association with the risk of VTE recurrence. In the whole 
population, there was no significant association between 
TLR9 rs5743836 polymorphism and risk of VTE recur-
rence (HR 1.12, CI 0.41–3.04, P = 0.827 and HR 0.99, 
CI 0.36–2.70, P = 0.981) on Uni- and multi-variate Cox 
regression analyses respectively. However, inclusion of an 
interaction term between TLR9 rs5743836 polymorphism 
and gender of the patients in the model showed a modifying 
effect of gender on TLR9 polymorphism (TLR9 polymor-
phism × gender: HR 2.49, 95% CI 1.08–5.74, P = 0.032). 
After stratification of data, according to gender, a signifi-
cant association between TLR9 rs5743836 polymorphism 
and risk of VTE recurrence was found in female patients 
on univariate Cox regression analysis (HR 3.60 and 95% CI 
1.11–11.61, P = 0.033) and on multivariate Cox regression 
analysis after adjusting for location of DVT, family his-
tory of VTE, mild and severe thrombophilia and acquired 
risk factors for VTE (HR 3.46, CI 1.06–11.33, P = 0.040). 
Similar results were found when we combined the T allele 
containing genotypes (TT and TC) and compared with 
homozygous mutated genotype (CC); only female patients 
having TLR9 rs5743836 polymorphism were at higher risk 
of VTE recurrence (HR 3.44, CI 1.07–11.0, P = 0.037 and 
HR 3.36, CI 1.04–10.88, P = 0.043 on univariate and multi-
variate Cox regression analyses respectively) (Table 2).
A survival analysis by Kaplan–Meier curve was per-
formed to analyze whether TLR9 rs5743836 polymorphism 
influences recurrence-free survival. Patients having T and 
C alleles were compared and results showed a significant 
difference in recurrence-free survival (Fig.  1a, Log-rank 
test, P = 0.037) in female patients. Female patients hav-
ing CC genotype had significantly shorter recurrence-free 
survival as compared to TT and TC genotypes, whereas no 
significant difference was observed between different geno-
types and risk of VTE recurrence in male patients (Fig. 1b, 
Log-rank test, P = 0.342).
TLR9 rs5743836 polymorphism and risk of VTE 
recurrence in patients with unprovoked first VTE
We also performed a sub-analysis on unprovoked first VTE 
patients (n = 618); patients with a recorded acquired risk 
factor for VTE, i.e., immobilization or cast therapy within 
the last month, use of contraceptives pills, surgical inter-
vention, malignancies diagnosed prior to or at diagnosis 
of the first VTE event, current pregnancy and postpartum 
period (first 6  weeks after delivery) and female hormone 
therapy were excluded from this analysis. Our results show 
an association between TLR9 rs5743836 polymorphism 
and risk of VTE recurrence, only in female unprovoked 
VTE patients, though this association did not reach statisti-
cal significance on univariate Cox regression analysis (HR 
3.79, CI 0.89–16.04, P = 0.071). However, on multivariate 
Cox regression analysis, after adjusting with location of 
DVT, family history of VTE, mild and severe thrombo-
philia, TLR9 polymorphism was significantly associated 
with the risk of VTE recurrence (HR 5.94, CI 1.25–28.13, 
P = 0.025) (Table 3).
Furthermore, sensitivity analyses were performed 
including all MATS patients (n = 1311) except those that 
had VTE before inclusion (n = 154). The follow-up time 
for these analyses was calculated from the time of inclu-
sion and was adjusted for duration of anticoagulant treat-
ment. Multivariate Cox regression analyses (adjusted for 
duration of anticoagulant treatment, mild and severe throm-
bophilia, location of DVT, family history and acquired risk 
factors for VTE), showed that female patients with TLR9 
rs5743836 polymorphism have significantly higher risk of 
VTE recurrence as compared to patients with wild-type 
genotype (HR 3.44, CI 1.05–11.26, P = 0.042) (Table 1 in 
the Supplementary Appendix).
Discussion
In the current study, we have analyzed TLR9 rs5743836 
polymorphism for its role in the risk assessment of VTE 
recurrence. Our results show that TLR9 rs5743836 poly-
morphism is significantly associated with higher risk of 
VTE recurrence in female patients, independent of known 
clinical risk factors associated with VTE recurrence. The 
HR for VTE recurrence in female patients was 3.46. In the 
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Table 1  Characteristics of 
studied population including the 
distribution of TLR9 rs5743836 
polymorphism genotypes 
stratified by recurrent and non-
recurrent status
DNA was not enough for genotyping in 12 samples for TLR9 rs5743836 polymorphism. P-value, Chi 
square test until unless indicated
significant P-values are shown in bold letters
DVT deep vein thrombosis, PE pulmonary embolism, BMI body mass index
*Mann–Whitney U test
¶ comparing non-recurrent with recurrent VTE
Parameters Mean (±SD) or n(%) Total n (%) P-value¶
Non recurrent 
VTE n (%)
Recurrent VTE n (%)
Age at inclusion
 Years (mean ± SD) 62.9 ± 17.5 61.3 ± 15.3 62.7 ± 17.3 0.087*
Gender
 Male 565 (48.6) 78 (52.7) 643 (49.0) 0.383
 Female 598 (51.4) 70 (47.3) 668 (51.0)
BMI
 Mean ± SD 26.6 ± 4.7 27.4 ± 5.1 26.6 ± 4.8 0.110*
PE
 PE 343 (29.5) 45 (30.4) 388 (29.6) 0.848
 No PE 820 (70.5) 103 (69.6) 923 (70.4)
DVT + PE
 DVT 820 (70.5) 103 (69.6) 923 (70.4) 0.306
 PE 277 (23.5) 32 (21.6) 309 (23.6)
 DVT + PE 66 (5.7) 13 (8.8) 79 (6)
Malignancy
 Yes 140 (12.1) 13 (8.8) 153 (11.7) 0.278
 No 1020 (87.9) 135 (91.2) 1155 (88.3)
Protein C deficiency
 Yes 16 (1.6) 0 (0.0) 16 (1.4) 0.242
 No 1009 (98.4) 1136 (100.0) 1145 (98.6)
Protein S deficiency
 Yes 20 (2.0) 1 (0.7) 21 (1.8) 0.499
 No 998 (98.0) 135 (99.3) 1133 (98.2)
Factor V mutations
 Yes 330 (28.5) 60 (40.8) 390 (29.9) 0.002
 No 829 (71.5) 87 (59.2) 916 (69.9)
Factor II mutations
 Yes 39 (3.9) 9 (7.0) 48 (4.2) 0.104
 No 969 (96.1) 120 (93.0) 1089 (95.8)
Antithrombin deficiency
 Yes 12 (1.2) 1 (0.7) 13 (1.1) 0.726
 No 1013 (98.8) 135 (99.3) 1148 (98.9)
Family history
 Yes 269 (23.5) 47 (32.4) 316 (24.5) 0.024
 No 875 (76.5) 98 (67.6) 973 (75.5)
TLR9 (rs5743836)
 TT 853 (74.0) 112 (76.2) 965 (74.3) 0.799
 TC 271 (23.5) 31 (21.1) 302 (23.2)
 CC 28 (2.4) 4 (2.7) 32 (2.5)
 TT and TC 1124 (97.6) 143 (97.3) 1267 (97.5) 0.777
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subgroup of unprovoked VTE recurrence in female patients, 
the HR was 5.94. To our knowledge, this is the first study 
in which TLR9 rs5743836 polymorphism has been studied 
in VTE recurrence. Previously, there was a single study in 
which this polymorphism has been studied for its role in 
primary deep vein thrombosis (DVT) and no association 
was found between TLR9 rs5743836 polymorphism and 
risk of DVT among a European population [27]. Recent 
studies have suggested that the risk factors for primary and 
recurrent VTE may differ [37, 38]. Furthermore, the above-
mentioned study [27] included only male patients, while 
our results suggest that TLR9 rs5743836 polymorphism 
is only associated with risk of VTE recurrence in female 
patients but not in male patients. It is now well established 
that the risk of VTE recurrence varies according to the gen-
der of the patients and risk factors for VTE recurrence are 
gender specific [32, 39]. Moreover, effects of sex hormones 
on inflammation in patients with and without TLR9 poly-
morphism may differ and thereby influence the risk of VTE 
recurrence in these patients [40, 41].
TLR9 rs5743836 polymorphism has been shown to 
affect the transcription activity of TLR9, CC genotype 
(mutant) was associated with lower transcription activity as 
compared to TT genotype (wild-type) [25]. Gene knockout 
studies have shown a pivotal role of TLR9 in VTE resolu-
tion [22, 23]. Taken together with our findings, this sug-
gests that TLR9 polymorphism may reduce the ability of 
VTE resolution and therefore may increase the risk of VTE 
recurrence.
We further analyzed TLR9 rs5743836 polymorphism in 
unprovoked VTE patients, which are known to have higher 
risk of VTE recurrence. We found a significant association 
between TLR9 rs5743836 polymorphism and VTE recur-
rence in female patients, independent of location of DVT, 
family history of VTE & mild and severe thrombophilia. 
These results show that TLR9 rs5743836 polymorphism 
may also be an independent risk factor for VTE recurrence 
in these higher risk female patients.
TLR9 is one of the important members of pattern recog-
nition receptors (PRRs) that are involved in thrombus reso-
lution. Leukocytes express several pattern PRRs (including 
TLR9) that are activated by damaged associated molecular 
patterns (DAMPs) from cellular debris, causing the release 
of mediators that promote sterile inflammation [23]. Leu-
kocytes, specially, neutrophils are known to be involved in 
the early thrombus resolution by promoting collagenolysis 
and fibrinolysis [42, 43] and monocytes are likely the most 
important cells involved in late VTE resolution [44]. Pro-
tective role of TLR9, as an integral part of thrombus reso-
lution process, due to the rs5743836 polymorphism may 
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In conclusion, for the first time, we have analyzed TLR9 
rs5743836 polymorphism in recurrent VTE patients. Our 
results suggest that TLR9 rs5743836 polymorphism is a 
potential marker for VTE recurrence in female but not in 
male patients. The findings shed new light on potential dif-
ferential mechanisms by gender in the development of VTE 
recurrence as well as on future preventive strategies.
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Fig. 1  Survival curves representing the different genotypes in TLR9 rs5743836 polymorphism and their association with risk of VTE recurrence 
in female (a) and male patients (b). P = log-rank test
Table 3  Uni- and multivariate analyses of TLR9 rs5743836 polymorphism in unprovoked recurrent VTE patients
significant P-values are shown in bold letters
*P adjusted for family history of VTE, mild and severe thrombophilia and location of VTE
Genotypes All unprovoked VTE patients Unprovoked women
Univariate HR (95% CI) P Multivariate HR (95% 
CI)
P* Univariate HR (95% 
CI)




 TT Reference Reference Reference Reference
 TC 0.91 (0.54–1.53) 0.723 0.92 (0.54–1.56) 0.746 1.27 (0.61–2.63) 0.519 1.13 (0.53–2.42) 0.756
 CC 0.65 (0.16–2.67) 0.553 0.60 (0.14–2.46) 0.474 3.79 (0.89–16.04) 0.071 5.94 (1.25–28.13) 0.025
 TT&TC Reference Reference Reference Reference
 CC 0.67 (0.16–2.72) 0.573 0.61 (0.15–2.50) 0.491 3.57 (0.86–14.94) 0.081 5.79 (1.23–27.19) 0.026
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